LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the platinum-resistant ovarian cancer market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat platinum-resistant ovarian cancer.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Platinum-resistant ovarian cancer: Market overview
Platinum-resistant ovarian cancer is a highly fatal disease and is the eighth most common cause of death in women. Patients with ovarian cancer have less than 47.4% chances of surviving for more than five years as per the analysis based on the data collected between 2008 and 2014. Though various chemotherapy drugs are available for the treatment of the disease, about 90% of all types of ovarian cancer become resistant to platinum and recur in six months of treatment, which makes it a deadly disease.
According to a senior analyst at Technavio for research on oncology, “The prevalence of ovarian cancer are not evenly spread across the world. It is more common in less developed countries with more developed nations. Nearly 58% of ovarian cancer cases are from less developed countries.”
Platinum-resistant ovarian cancer segmentation
This market research report segments the platinum-resistant ovarian cancer market based on therapies employed that includes combination therapy and monotherapy, RoA (intravenous, oral, subcutaneous, intradermal, intraperitoneal, and unknown), therapeutic modalities (monoclonal antibody, small molecules, vaccine, marine-derived, adenovirus, gene therapy, and undisclosed), targets for drugs under development (programmed cell death 1, PARP, VEGF, CSF1, DNA, folate receptor alpha, unknown, and others), MoA (PDCD1 inhibitor, PARP inhibitor, VEGF inhibitor, CSF1 inhibitor, DNA inhibitor, folate receptor alpha antagonist, unknown, and others) drugs under development (pre-clinical, phase I, phase Ia, phase I/II, phase II, and phase III), and recruitment status (recruiting, active not recruiting, not yet recruiting, completed, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
- Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.